Premet

Quick links to important sections

Premet

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Premet

Property Description
Active Ingredients Pregabalin, Mecobalamin (Methylcobalamin)
Form Oral Solid Dosage Form (Tablet or Capsule)
Pharmacological Class Anticonvulsant (GABA Analogue) and Vitamin (B12) Supplement Combination
General Purpose Support for Nerve Health and Symptom Relief
Origin Synthetic (Pregabalin) and Bio-identical Vitamin (Mecobalamin)

What is Premet and its Pharmacological Classification?

Premet is a prescription-only medicine supplied as a Fixed-Dose Combination (FDC) taken orally, typically as a tablet or capsule. Its pharmacological classification is a combined Anticonvulsant (GABA Analogue) and Vitamin (B12) Supplement Combination. This duality reflects a clinical strategy to address both the neurological signaling aspects and the nutritional requirements of nerve health. As an FDC, it provides both active components simultaneously, representing a specific and consolidated approach to nerve impairment management.

Composition and Origin of the Active Ingredients

Premet's composition is defined by its two principal active ingredients: Pregabalin and Mecobalamin (Methylcobalamin). Pregabalin is a synthetic compound structurally classified as a gamma-aminobutyric acid (GABA) analogue. Mecobalamin, conversely, is the bio-identical, active coenzyme form of Vitamin B12. The inclusion of Mecobalamin, rather than less active B12 forms like Cyanocobalamin, is a compositional feature intended to provide immediate metabolic support to nerve tissues.

General Purpose: Addressing Nerve Structure and Signaling

Premet's general purpose is to achieve a synergistic effect by managing nerve-related discomfort while supporting structural integrity. The Pregabalin component is designed to modulate overactive nerve signals, which are often associated with chronic pain states. Concurrently, the Mecobalamin component facilitates metabolic reactions that are vital for myelin sheath synthesis and general nerve regeneration. This dual action offers a foundational approach to supporting the peripheral nervous system against chronic impairment.

Regulatory References

  1. National Library of Medicine, MedlinePlus

What side effects are possible with Premet?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics associated with the active components of Premet, based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

The most frequently reported effects are related to the central nervous system and metabolism. According to regulatory data, dizziness and somnolence (drowsiness) are classified as most common. Other effects considered common include peripheral edema (swelling in the hands or feet), weight gain, dry mouth, and blurred vision. Reactions are grouped across system-organ classes, including Nervous System Disorders, Metabolism and Nutrition Disorders, and Psychiatric Disorders.

Serious Adverse Reactions

Regulatory documents highlight several serious safety concerns that require observation. These include the potential for severe respiratory depression, particularly when the medicine is used with other CNS depressants, and the risk of life-threatening angioedema (swelling of the face, tongue, or throat) and other serious hypersensitivity reactions. Additionally, an increased risk of suicidal thoughts or behavior is associated with anticonvulsant medications.

Population-Specific and Time-Related Safety

Specific safety considerations are defined for certain patient groups. Patients with renal impairment require mandatory dose adjustment to prevent increased exposure, and older adults are noted to be at higher risk for certain adverse events and falls. Furthermore, abrupt or rapid discontinuation of the medicine may lead to defined withdrawal symptoms (e.g., anxiety, headache, insomnia) or an increased risk of seizures, necessitating gradual tapering as an official safety constraint.

Overdose and Emergency Response

Overdose with Premet, primarily due to the Pregabalin component, is officially documented to present with clinical signs of central nervous system (CNS) depression. Manifestations may include somnolence, a confusional state, and agitation, which may progress to more severe presentations such as convulsions, loss of consciousness, or coma. Serious, life-threatening outcomes cited in regulatory information include respiratory depression, particularly when the medicine is taken alongside other CNS depressants. Rare reports of serious cardiac effects, including heart block and cardiac arrest, have also been documented in the postmarketing setting.

Immediate Medical Action Required

Government regulatory sources explicitly mandate that emergency medical attention must be sought immediately upon any suspicion of overdose. Patients and caregivers are instructed to contact emergency services without delay, especially if signs of severe CNS or respiratory distress occur. Because no specific antidote is known for Pregabalin overdose, the official management strategy focuses on providing general supportive care to maintain vital functions. This includes continuous monitoring of clinical status and vital signs. For severe cases, procedural steps such as gastric lavage or hemodialysis may be considered to remove the drug, particularly for patients with compromised renal function.

Therapeutic Uses of Premet

The combination of active ingredients is relevant for addressing conditions involving nerve damage and chronic pain, focusing on symptom relief and structural support.


Management of Chronic Neuropathic Pain Syndromes

This combination is primarily used to address the ongoing, debilitating pain associated with damaged or malfunctioning nerve fibers, such as Diabetic Peripheral Neuropathy and Postherpetic Neuralgia. Pregabalin is used to relieve neuropathic pain, which often presents as burning, stabbing pain, or aches. It is applied in situations requiring management of chronic, persistent discomfort that is typically not relieved by general painkillers. Conditions where this combination is commonly used to help manage symptoms include: diabetic peripheral neuropathy, postherpetic neuralgia, and pain associated with fibromyalgia. It may help patients cope more steadily with symptom fluctuations and supports improved day-to-day comfort.

Relief of Exaggerated Nerve Sensations and Support

The combination is relevant for easing the distressing sensory disturbances characteristic of nerve pain. This covers symptoms like burning, stabbing, shooting, or electric shock-like feelings, as well as uncomfortable sensations such as persistent tingling or prickling (paresthesia). Managing these symptoms may assist with easing their impact on routine daily functioning and supports better, undisturbed rest. Beyond symptomatic management, the Mecobalamin (Vitamin B12) component provides nutritional assistance that supports nerve tissue.

“This approach is relevant for easing the symptom load in conditions where discomfort arises directly from nerve dysfunction.”


Quick Fact: Commonly used for managing symptoms such as Positive Sensory Disturbances (e.g., burning, stabbing pain) and Paresthesia (tingling, numbness).

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Premet?

This section defines population eligibility for Premet (Pregabalin/Mecobalamin FDC) based strictly on official regulatory labeling, including contraindications and use limitations.


Contraindications and Absolute Restrictions

Premet is contraindicated and must not be used in patients with a documented hypersensitivity to pregabalin, mecobalamin, or any of the inactive ingredients. It is also contraindicated for patients with Leber's Hereditary Optic Neuropathy.

Age and Physiological Limitations

Population Group Eligibility Status (Regulatory Wording)
Adults (ge 18 years) Established use for approved indications.
Pediatric (< 18 years) Use not established and not recommended for neuropathic pain.
Renal Impairment Conditional use; dose adjustment is mandatory due to decreased drug clearance.
Pregnancy/Lactation Not recommended during pregnancy unless benefits outweigh risks; breastfeeding should be discontinued.

Conditional Use and Precautions

Caution is advised for the elderly who may require a dose adjustment due to age-related decline in kidney function. Additionally, conditional use is required for patients with a current or past history of substance use disorder due to the potential for dependence liability and those with pre-existing compromised respiratory function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns involving the active ingredients of Premet (Pregabalin and Mecobalamin), strictly based on official regulatory sources.


Pharmacodynamic Interactions: CNS Depressants

The primary interactions involve additive pharmacodynamic effects due to the Pregabalin component. Co-administration with other Central Nervous System (CNS) depressants is documented to increase the risk of respiratory depression, dizziness, and somnolence. Official labeling cautions against co-consumption with alcohol, opioids, and benzodiazepines due to this enhanced risk.

Thiazolidinedione antidiabetic agents (a class of diabetes medicine) are also cited with caution due to a possible enhanced, additive risk of peripheral edema (swelling of the extremities).


Pharmacokinetic Profile and Absorption

Pregabalin is largely excreted unchanged by the kidneys and is officially documented as being unlikely to be involved in significant pharmacokinetic drug-drug interactions because it neither induces nor inhibits major Cytochrome P450 (CYP) enzymes. Consequently, no clinically significant pharmacokinetic interactions are documented with common antiepileptic drugs (AEDs).

Conversely, the Mecobalamin ( Vitamin B12) component may be subject to absorption modification. Regulatory documents note that the concurrent use of Proton Pump Inhibitors (PPIs) and H2-receptor antagonists may reduce the oral absorption of Vitamin B12.

In terms of renal clearance, regulatory information notes that patients with reduced renal function exhibit decreased Pregabalin clearance, leading to higher systemic exposure.

Mechanism of Action

Premet’s action is defined by a dual mechanistic engagement, combining the immediate modulation of nerve signaling with influence on metabolic pathways critical for nerve structure.

The Pregabalin component acts as a high-affinity functional modulator of the alpha2-delta subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs). This binding limits the trafficking of VGCCs to the nerve ending membrane, which reduces the excessive influx of calcium ions and consequently decreases the pathological release of excitatory neurotransmitters like glutamate. This molecular mechanism results in the physiological consequence of reduced neuronal hyperexcitability and altered sensory signal transmission within the central nervous system. The action is state-dependent, primarily affecting neurons that are already pathologically overactive.

The Mecobalamin (Methylcobalamin) component is an active cofactor necessary for the enzyme Methionine Synthase in the one-carbon metabolic pathway. Its function is to facilitate the production of S-Adenosylmethionine (SAMe), which is crucial for the methylation reactions required for myelin sheath synthesis and general protein synthesis in nerve cells. This mechanism influences metabolic pathways that govern the synthesis of components crucial for peripheral nervous system structure, affecting the integrity and maintenance of nerve tissue; this process is slower and cumulative compared to the immediate neuromodulation.

Dosage and Administration Information

How Premet is Used: Official Administration Guidelines

Premet, a Fixed-Dose Combination (FDC) containing Pregabalin and Mecobalamin, is administered solely by the oral route as a capsule or tablet. The official usage pattern is defined by a highly structured regimen for the Pregabalin component, ensuring a measured and gradual approach to therapy.


Standard Dosing and Frequency

Therapy typically begins with a low initial dose of the Pregabalin component, such as 150 mg per day, which is taken in divided doses (usually twice or three times daily). The dosage is gradually increased over time to reach a maintenance range based on the official titration schedule. The maximum daily dose of the Pregabalin component is generally restricted to 600 mg in divided doses. The medicine may be taken with or without food, although some labels may specify intake before food.


Titration and Discontinuation

Usage involves a gradual titration phase. Dose increases should occur slowly, typically over a minimum of one week between adjustments. Conversely, when discontinuing the medicine, the dose must be tapered gradually over a minimum of one week to follow the official procedural instruction for cessation of therapy.


Population-Specific Adjustments

A mandatory dose adjustment is required for patients with renal impairment, as the Pregabalin component is eliminated almost entirely by the kidneys. The specific regimen is determined by the patient's measured creatinine clearance. Additionally, due to potential age-related reductions in kidney function, older adults (>65 years) may necessitate a lower starting dose.

Recent Clinical Evidence

Premet: Recent Clinical Evidence

The research for Premet (Pregabalin and Mecobalamin combination) focuses on understanding the evidence context for conditions associated with nerve damage. The available evidence is generally drawn from a mix of open-label observational studies, comparative pilot trials, and post-marketing surveillance, rather than large-scale, double-blind, placebo-controlled trials specifically dedicated to this fixed-dose combination.


Evidence for use in Painful Peripheral Neuropathy

Research explored the Premet combination in adults experiencing chronic pain due to general nerve damage, a condition often characterized by fluctuating or episodic manifestations such as burning, stabbing, or tingling sensations. The main outcomes related to physical discomfort studies explored using standardized tools, such as the Numerical Pain Intensity Scale, along with questionnaires evaluating patient-reported outcomes describing perceived discomfort and sleep quality.

In these research scenarios, the studies monitored how patients' pain intensity and sleep interference scores were measured in the observed populations over defined time intervals. However, the evidence quality varies across studies, and many reports rely on open-label designs, which may influence how patients report their experience. The results apply only to the populations studied and may not entirely reflect experiences in other patient groups.


Evidence for use in Diabetic Peripheral Neuropathy (DPN)

Research evaluated the combination in specific studies exploring how symptoms change over time in adults whose nerve pain is associated with Type 2 Diabetes Mellitus. Beyond measuring pain and sleep, researchers in these trials also examined physiological measures like Nerve Conduction Velocity (NCV). Certainty remains low in some of this area because a number of these studies were pilot trials with sample sizes that were modest. This means they were not large enough to establish statistical certainty about the combination’s effect compared to a non-active treatment.


Understanding the Strength and Gaps in the Evidence

The evidence quality varies across studies for the fixed-dose combination. Research provides context but not individual predictions. The available findings describe patterns observed in the studies but do not determine whether an individual will respond similarly. The evidence for long-term observations is not fully established, and current follow-up durations were limited.

Frequently Asked Questions (FAQ)

Common questions about Premet (FAQ)


Q: Does Premet have a black box warning in the US?

A: US regulatory warnings highlight serious safety concerns associated with the medication. These include the potential for severe respiratory depression when the medicine is used with other Central Nervous System (CNS) depressants, and the risk of suicidal thoughts or behavior associated with its class of anticonvulsant medicines.


Q: Are there any long-term health risks associated with Premet use?

A: Official information indicates that evidence from clinical trials regarding long-term observations is limited, meaning follow-up durations were often short. The drug’s official safety profile notes dependence liability and includes weight gain and peripheral edema (swelling) as reported effects that may continue over time.


Q: Is Premet considered a controlled substance?

A: Yes, Premet is a prescription-only medicine and is subject to specific regulatory classification. In the US, the Pregabalin component is classified by the Drug Enforcement Administration (DEA) as a Schedule V controlled substance, reflecting a low potential for abuse or dependence relative to other scheduled drugs.


Q: Does Premet interact with over-the-counter cold medicines?

A: Official prescribing information advises caution against combining Premet with other Central Nervous System (CNS) depressants. Some over-the-counter cold or allergy medicines may contain these depressants, and the combination could increase the risk of side effects like dizziness and somnolence (drowsiness).


Q: Is it normal to feel no immediate change after starting Premet?

A: The lack of immediate change is consistent with the drug’s dual mechanism of action. While the Pregabalin component acts on nerve signaling relatively quickly, the Mecobalamin component works through slower, cumulative metabolic processes to support nerve structure.


Q: Do you need a special kind of prescription to get Premet?

A: Premet is a prescription-only medicine. Because of its potential for dependence, its classification as a Schedule V controlled substance in the US means it requires specific regulatory controls for prescribing and dispensing, distinguishing it from non-controlled prescription drugs.


Q: What does 'contraindication' mean in the context of Premet?

A: In the context of Premet, a contraindication is a factor or condition that absolutely prevents the medicine from being used. For example, official labeling states that Premet is contraindicated if a patient has a known hypersensitivity or severe allergy to any of its components.


Q: Does Premet have a known effect on mood or anxiety?

A: Official safety data indicates the medicine is associated with a risk of suicidal thoughts or behavior. Furthermore, changes in mood or feelings of euphoria have been reported as side effects, and anxiety is a known symptom that may occur if the medicine is stopped abruptly.


Q: Are there different forms or strengths of Premet available?

A: Yes, Premet is supplied as an oral tablet or capsule (solid dosage form). The specific fixed-dose strengths, which contain varying amounts of Pregabalin and Mecobalamin, will be determined by the regional regulatory approval.


Q: How quickly should I expect Premet to start working?

A: The Pregabalin component reaches its peak concentration within approximately 0.7 to 1.3 hours. However, achieving the full therapeutic effect depends on the specific condition being treated, the gradual dose titration schedule, and is linked to the cumulative action of Mecobalamin.


Q: If I miss a dose of Premet, what is the standard information given?

A: Official patient instructions describe a procedure for addressing a missed dose, typically involving taking the dose when remembered unless the next dose is due. Regulatory information states that taking two doses simultaneously is not recommended.


Q: Is it safe to drink coffee or caffeine while taking Premet?

A: According to the official prescribing information, no clinically significant interactions have been reported or noted regarding the co-consumption of caffeine with the active ingredients of Premet.


Q: Is Premet typically taken for a short time or long-term?

A: Premet is approved for the management of chronic conditions, such as neuropathic pain. Therefore, the duration of use is often long-term, but it is ultimately determined by the prescribing health professional based on the individual condition and response.


Q: What is the general duration of effect for a Premet dose?

A: The Pregabalin component has an elimination half-life of approximately 6.3 hours in adults with normal kidney function. This pharmacokinetic characteristic is the basis for the medicine being typically administered in divided doses throughout the day.


Q: Can Premet cause stomach upset or digestive issues?

A: Official safety profiles list dry mouth as a common side effect. Other gastrointestinal adverse effects that have been reported include issues such as diarrhea and nausea.


Q: How does Premet affect liver function, according to official information?

A: Official pharmacokinetic data shows that the Pregabalin component is minimally processed by the liver, undergoing negligible metabolism in humans. It is primarily excreted unchanged by the kidneys. The data indicates a minimal direct role with the liver’s main drug-metabolizing enzyme systems.


Q: Are headaches a commonly reported side effect of Premet?

A: Headache is not classified as a most common adverse reaction during continuous use of Premet. However, it is a symptom that has been formally reported during the tapering or abrupt discontinuation phase of the medicine.


Q: Can Premet be taken at the same time as antacids?

A: Official regulatory documents indicate that there are no clinically significant pharmacokinetic interactions reported between the active ingredients of Premet and most common antacids.


Q: Is Premet safe to use for people with high blood pressure?

A: There is no absolute contraindication based solely on high blood pressure. However, caution is advised for patients with certain heart problems (like congestive heart failure) due to the potential for peripheral edema (swelling) as a side effect.


Q: What precautions are listed for driving or operating machinery while on Premet?

A: Due to the common adverse reactions of dizziness and somnolence (drowsiness), official labeling states that the medicine may impair a person's ability to drive or operate complex machinery. Official labeling highlights the importance of recognizing the drug’s effects before engaging in such activities.


Q: What if I experience a rare or unexpected side effect with Premet?

A: Official patient information describes that users should contact their healthcare provider immediately if they experience any serious, unusual, or unexpected symptoms. Users are also encouraged to report adverse events to their country's drug regulatory authority, such as the FDA.


Q: Can Premet affect blood sugar levels?

A: Regulatory information notes that diabetic patients who experience weight gain while taking Premet may require an adjustment to their hypoglycemic treatment (diabetes medicines). The relationship between weight gain and blood sugar management is a reported clinical consideration for this population.


Q: What is the standard recommendation if Premet causes drowsiness?

A: Official documents describe that due to the risk of drowsiness, the recommended safety precaution is to avoid activities requiring mental alertness, such as driving or operating complex machinery, until a person knows how the medicine affects them.


Q: Does Premet show up on standard drug tests?

A: The Pregabalin component of Premet is generally not included in standard, routine drug screens, such as 5- or 10-panel workplace tests. It would only be detected if a specific toxicology panel for Pregabalin was requested.

How should Premet be stored and disposed of?

Official Storage and Handling Requirements

Premet must be stored according to the conditions specified in its official regulatory labeling to maintain quality and stability. The medicine should be stored at a temperature below 30°C and must be kept in a dry place.

It is mandatory to protect the product from light and keep it in the original container, with the container tightly closed. This is essential to prevent degradation, particularly of the Mecobalamin component. As with all medicines, Premet must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Premet must be disposed of following official government guidelines. Patients should use an official drug take-back program if one is available. If a take-back option is not accessible, the medicine should be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash. Do not dispose of Premet by flushing it down the toilet or pouring it down the sink unless explicitly instructed by a regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Premet found in:

A-Z Index: